Angiomax is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Sandoz Inc. The primary component is Bivalirudin.
| Product ID | 0781-3447_5f133813-f74e-4508-bc64-debbf104ff1e |
| NDC | 0781-3447 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Angiomax |
| Generic Name | Bivalirudin |
| Dosage Form | Injection |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2019-08-01 |
| Marketing Category | NDA / NDA |
| Application Number | NDA020873 |
| Labeler Name | Sandoz Inc |
| Substance Name | BIVALIRUDIN |
| Active Ingredient Strength | 250 mg/1 |
| Pharm Classes | Anti-coagulant [EPC],Direct Thrombin Inhibitor [EPC],Thrombin Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |
| Marketing Start Date | 2019-08-01 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA020873 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2019-08-01 |
| Ingredient | Strength |
|---|---|
| BIVALIRUDIN | 250 mg/1 |
| SPL SET ID: | 5f133813-f74e-4508-bc64-debbf104ff1e |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0781-3447 | Angiomax | bivalirudin |
| 65293-001 | Angiomax | bivalirudin |
| 0409-8300 | Bivalirudin | BIVALIRUDIN |
| 0781-3158 | bivalirudin | bivalirudin |
| 0781-9158 | bivalirudin | bivalirudin |
| 16729-275 | Bivalirudin | Bivalirudin |
| 25021-405 | bivalirudin | bivalirudin |
| 52958-034 | Bivalirudin | Bivalirudin |
| 55111-652 | Bivalirudin | Bivalirudin |
| 55150-210 | BIVALIRUDIN | BIVALIRUDIN |
| 60505-6101 | Bivalirudin | bivalirudin |
| 63323-562 | Bivalirudin | Bivalirudin |
| 67457-256 | Bivalirudin | bivalirudin |
| 69097-601 | bivalirudin | bivalirudin |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() ANGIOMAX 75758548 2427591 Live/Registered |
SANDOZ INC. 1999-07-23 |